Ozoralizumab: First Approval

Drugs. 2023 Jan;83(1):87-92. doi: 10.1007/s40265-022-01821-0.

Abstract

Ozoralizumab (Nanozora®), a trivalent anti-tumour necrosis factor alpha (TNFα) NANOBODYⓇ compound, has been developed by Taisho Pharmaceutical Co. Ltd (under license from Ablynx, an affiliate of Sanofi) for the treatment of rheumatoid arthritis (RA). In September 2022, ozoralizumab was approved in Japan for the treatment of RA that is inadequately managed by current available treatments. This article summarizes the milestones in the development of ozoralizumab leading to this first approval.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use
  • Arthritis, Rheumatoid* / drug therapy
  • Humans
  • Japan
  • Tumor Necrosis Factor-alpha

Substances

  • Antibodies, Monoclonal
  • Tumor Necrosis Factor-alpha